Anya Biopharm Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	24.83	21.6	2.32	2.5
Revenue Growth (YoY)	1369.47%	831.26%	-7.09%	-
Cost of Revenue	0.14	0.14	0.09	0.09
Gross Profit	24.69	21.46	2.23	2.41
Selling, General & Admin	27.82	33.56	10.81	8.54
Research & Development	39.72	30.75	20.03	32.67
Operating Expenses	67.54	64.31	30.85	41.21
Operating Income	-42.84	-42.85	-28.62	-38.8
Interest Expense	-0.56	-0.34	-0.02	-0.02
Interest & Investment Income	13.35	5.21	0.02	0
Currency Exchange Gain (Loss)	-42.64	3.27	0.54	-2.96
Other Non Operating Income (Expenses)	-	0	0.03	-0
Pretax Income	-72.69	-34.72	-28.05	-41.78
Income Tax Expense	2.36	2.13	0.03	0.04
Earnings From Continuing Operations	-75.05	-36.84	-28.08	-41.82
Minority Interest in Earnings	-0.14	-0.12	0	-0.01
Net Income	-75.19	-36.96	-28.08	-41.83
Net Income to Common	-75.19	-36.96	-28.08	-41.83
Shares Outstanding (Basic)	49	33	2	2
Shares Outstanding (Diluted)	49	33	2	2
Shares Change (YoY)	415.67%	1351.36%	-	-
EPS (Basic)	-1.53	-1.12	-12.32	-18.35
EPS (Diluted)	-1.53	-1.12	-12.32	-18.35
Free Cash Flow	-63.77	-30.17	-24.2	-44.16
Free Cash Flow Per Share	-1.29	-0.91	-10.61	-19.37
Gross Margin	99.43%	99.36%	96.16%	96.55%
Operating Margin	-172.52%	-198.43%	-1233.98%	-1554.37%
Profit Margin	-302.77%	-171.14%	-1210.82%	-1675.92%
Free Cash Flow Margin	-256.76%	-139.69%	-1043.60%	-1769.15%
EBITDA	-41.68	-42.17	-28.19	-38.66
EBITDA Margin	-167.84%	-195.25%	-	-
D&A For EBITDA	1.16	0.69	0.42	0.14
EBIT	-42.84	-42.85	-28.62	-38.8
EBIT Margin	-172.52%	-198.43%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.